NEW YORK (GenomeWeb News) – Molecular diagnostics firm Cepheid today said that it has received the CE Mark for its test that rapidly identifies the vanA and/or vanB genes, which are most commonly associated with vancomycin-resistant Enterococci.
The Sunnyvale, Calif.-based firm also said that it has launched the Xpert vanA/vanB test, which provides results in 45 minutes and runs on the company’s GeneXpert System. It is the first test developed and manufactured by Cepheid’s Swedish subsidiary, Cepheid AB.